Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
Key Highlights
- ➤Viatris (VTRS) commenced tender offer to acquire Pacira (PCRX) for $36.50 per share cash
- ➤Pacira Board unanimously recommended shareholders accept Viatris’ $36.50-per-share offer
- ➤Offer expires one minute after 11:59 p.m. ET on Nov. 16, 2026
- ➤Pacira will become Viatris’ wholly owned subsidiary after merger completion
- ➤Offer requires majority tender condition and HSR waiting-period expiration, with no financing condition
Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc. PR Newswire
PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Pacira BioSciences, Inc. ("Pacira") (Nasdaq: PCRX), for $36.50 per Share, in cash, net of applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated Oct. 30, 2026 (as it may be amended or supplemented from time to time, the "Offer to Purchase"), and the accompanying Letter of Transmittal (the "Letter of Transmittal" and, together with the Offer to Purchase and other related materials, as they may be amended or supplemented from time to time, the "Offer").
Get started
Create a free account to read the full story.